CCCC
C4 Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CCCC
C4 Therapeutics, Inc.
A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform
Biological Technology
10/07/2015
10/02/2020
NASDAQ Stock Exchange
110
12-31
Common stock
490 Arsenal Way, Suite 200, Watertown, MA 02472
--
C4 Therapeutics, Inc., was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company dedicated to harnessing the body's natural regulation of protein levels to develop new therapeutic drug candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.
Company Financials
EPS
CCCC has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.38, missing expectations. The chart below visualizes how CCCC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CCCC has released its 2025 Q3 earnings report, with revenue of 11.23M, reflecting a YoY change of -26.90%, and net profit of -32.17M, showing a YoY change of -30.41%. The Sankey diagram below clearly presents CCCC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
